newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric